AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31050056 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Strengthening Programme
Number of subjects: 501
Study 28177751 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic fatigue group (n = 15) with 10 sets of 20 repetitions of maximal isokinetic knee extensor contractions at 300°·s‐1
Number of subjects: 42
Study 28177751 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric fatigue group (n = 15) with 10 repetitions of 6‐s knee extensor MVIC
Number of subjects: 42
Study 28177751 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12) were not fatigued
Number of subjects: 42
Study 24930949 — intervention group
Group type: EXPERIMENTAL
Intervention: GreenLight™ Simulator training (novice group: 12 participants, 10 sessions of subtask training modules followed by a long operative case)
Number of subjects: 46
Study 24930949 — intervention group
Group type: EXPERIMENTAL
Intervention: GreenLight™ Simulator training (intermediate and expert groups: 14 and 7 participants respectively, performed all training modules once followed by one operative case)
Number of subjects: 46
Study 24174677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic face presentation
Number of subjects: 0
Study 24174677 — intervention group
Group type: EXPERIMENTAL
Intervention: Static face presentation
Number of subjects: 0
Study 24174677 — intervention group
Group type: EXPERIMENTAL
Intervention: Connections modulated by dynamic and static fear from amygdala
Number of subjects: 0
Study 21836511 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus, mycophenolate mofetil and steroids
Number of subjects: 15
Study 19680260 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine (first-line therapy)
Number of subjects: 232
Study 19680260 — intervention group
Group type: COMPARATOR
Intervention: Azelnidipine (converted from amlodipine)
Number of subjects: 232
Study 17554712 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-lamivudine
Number of subjects: 213
Study 17554712 — intervention group
Group type: COMPARATOR
Intervention: Stavudine-didanosine
Number of subjects: 213
Study 17554712 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 213
Study 17554712 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir
Number of subjects: 213
Study 15756168 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon (QT group)
Number of subjects: 48
Study 15756168 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon (PT group)
Number of subjects: 48
Study 11159250 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.125% bupivacaine with clonidine 1 microg/mL and sufentanil 0.1 microg/mL at 10 mL/h (Group 1)
Number of subjects: 45
Study 11159250 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA boluses of 10 mL/h of 0.125% bupivacaine with clonidine 1 microg/mL and sufentanil 0.1 microg/mL (Group 2)
Number of subjects: 45
Study 11159250 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA boluses of 5 mL per 30 min of 0.125% bupivacaine with clonidine 1 microg/mL and sufentanil 0.1 microg/mL (Group 3)
Number of subjects: 45
Study 9626725 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative management programme including patient education, on-site mental health treatment, adjustment of antidepressant medication, behavioural activation and monitoring of medication adherence
Number of subjects: 0
Study 9626725 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 8049826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (O3) alone
Number of subjects: 45
Study 8049826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (O3) + Sulfuric acid (H2SO4)
Number of subjects: 45
Study 8049826 — intervention group
Group type: COMPARATOR
Intervention: Sulfuric acid (H2SO4) alone
Number of subjects: 45
Study 8049826 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 45
Study 3355357 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EN, n = 18) and Exercise with light weights (EW, n = 17)
Number of subjects: 47
Study 3355357 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising controls (C, n = 12)
Number of subjects: 47
Study 3355357 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EN, n = 18)
Number of subjects: 47
Study 3355357 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with light weights (EW, n = 17)
Number of subjects: 47
Study 31419002 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticocancellous FDBA blocks
Number of subjects: 28
Study 31419002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous FDBA blocks
Number of subjects: 28
Study 31419002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 28606499 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional somatic syndromes (FSS) patients
Number of subjects: 273
Study 28606499 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional somatic syndromes (FSS) patients with mild SSS
Number of subjects: 273
Study 28606499 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional somatic syndromes (FSS) patients with moderate SSS
Number of subjects: 273
Study 28606499 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional somatic syndromes (FSS) patients with severe SSS
Number of subjects: 273
Study 25875753 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 291
Study 25875753 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy plus endoscopic papillary balloon dilation (EST-EPBD)
Number of subjects: 291
Study 23970363 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 21
Study 23970363 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 21
Study 21969666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch spiral scanning in group A
Number of subjects: 272
Study 21969666 — intervention group
Group type: COMPARATOR
Intervention: Sequential scanning in group A
Number of subjects: 272
Study 21969666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential scanning in group B
Number of subjects: 272
Study 21969666 — intervention group
Group type: COMPARATOR
Intervention: Retrospective spiral scanning in group B
Number of subjects: 272
Study 21969666 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-window prospective sequential scanning in group A
Number of subjects: 272
Study 21969666 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-window prospective sequential scanning in group B
Number of subjects: 272
Study 21969666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch spiral scanning in subpopulation (<55 beats per minute)
Number of subjects: 272
Study 18847416 — intervention group
Group type: EXPERIMENTAL
Intervention: New immunosuppressive drugs (specific drugs not mentioned)
Number of subjects: 0
Study 18847416 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors
Number of subjects: 0
Study 18847416 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose or calcineurin inhibitor-free regimens
Number of subjects: 0
Study 16314018 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Movement Test (RMT)
Number of subjects: 36
Study 16314018 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of sensory information
Number of subjects: 36
Study 16314018 — intervention group
Group type: EXPERIMENTAL
Intervention: Errors in time
Number of subjects: 36
Study 16314018 — intervention group
Group type: EXPERIMENTAL
Intervention: Errors in space
Number of subjects: 36
Study 14568898 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD+ITD CPR
Number of subjects: 210
Study 14568898 — intervention group
Group type: COMPARATOR
Intervention: S-CPR
Number of subjects: 210
Study 10908942 — intervention group
Group type: EXPERIMENTAL
Intervention: Light mobilization program with information and advice to stay active
Number of subjects: 457
Study 10908942 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary health care (control group)
Number of subjects: 457
Study 8958267 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 0
Study 8958267 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppression (cyclosporine and steroids)
Number of subjects: 0
Study 8958267 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(‐7) M prednisolone in vitro
Number of subjects: 0
Study 1540881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with 5‐fluorouracil (5‐FU), doxorubicin, and mitomycin C (FAM)
Number of subjects: 142
Study 1540881 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy with mitomycin C, followed by doxorubicin on disease progression, followed by 5‐FU
Number of subjects: 142
Study 1540881 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary therapy with doxorubicin alone
Number of subjects: 142
Study 1540881 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary therapy with 5‐FU alone
Number of subjects: 142
Study 1540881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (FAM)
Number of subjects: 142
Study 1540881 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 142
Study 3904899 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque
Number of subjects: 49
Study 3904899 — intervention group
Group type: COMPARATOR
Intervention: Urografin
Number of subjects: 49
Study 3904899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Omnipaque and Urografin
Number of subjects: 49
Study 30738701 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stocking on one leg during a three-hour flight
Number of subjects: 34
Study 29767420 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 39
Study 29767420 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eye)
Number of subjects: 39
Study 26093535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose green tea extract (EGCG) at a daily dosage of 856.8 mg
Number of subjects: 102
Study 26093535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose green tea extract (EGCG)
Number of subjects: 102
Study 26093535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 24925303 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto‐oligosaccharides (GOS) (2·5 g; three times per d) during and 7 d after AMX treatment
Number of subjects: 12
Study 24925303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, n 6) (2·5 g; three times per d) during and 7 d after AMX treatment
Number of subjects: 12
Study 24925303 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS
Number of subjects: 12
Study 24925303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22861655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality during the last week
Number of subjects: 411
Study 22861655 — intervention group
Group type: COMPARATOR
Intervention: Sleep quality preadmission
Number of subjects: 411
Study 22861655 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous hospitalization and operation experience
Number of subjects: 411
Study 22861655 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who underwent a major surgical procedure
Number of subjects: 411
Study 22861655 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients hospitalized for a week
Number of subjects: 411
Study 22861655 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing medical intervention during sleeping hours
Number of subjects: 411
Study 22861655 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic illness history and postponed operations
Number of subjects: 411
Study 21137666 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal after 1 day
Number of subjects: 189
Study 21137666 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal after 2 days
Number of subjects: 189
Study 21137666 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal after 4 days
Number of subjects: 189
Study 17980217 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 133
Study 17980217 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and weight loss
Number of subjects: 133
Study 17980217 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 133
Study 15109358 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electroacupuncture (phase I)
Number of subjects: 40
Study 15109358 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (phase II)
Number of subjects: 40
Study 15109358 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electroacupuncture (phase II)
Number of subjects: 40
Study 15109358 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (phase I)
Number of subjects: 40
Study 12006310 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls nurse intervention
Number of subjects: 348
Study 12006310 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 348
Study 9653595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg t.i.d.
Number of subjects: 126
Study 9653595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 8131533 — intervention group
Group type: COMPARATOR
Intervention: Room Air (RA)
Number of subjects: 276
Study 8131533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (O2, 6 L/min by nasal cannula)
Number of subjects: 276
Study 2480147 — intervention group
Group type: COMPARATOR
Intervention: Iloprost (1 ng/kg/body weight for 45 min)
Number of subjects: 8
Study 2480147 — intervention group
Group type: COMPARATOR
Intervention: Iloprost (2 ng/kg/body weight for 45 min)
Number of subjects: 8
Study 2480147 — intervention group
Group type: COMPARATOR
Intervention: Iloprost (4 ng/kg/body weight for 45 min)
Number of subjects: 8
Study 2480147 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (saline infusion for 45 min)
Number of subjects: 8
Study 30446246 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin before primary angioplasty (AST)
Number of subjects: 103
Study 30446246 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (ST)
Number of subjects: 103
Study 25731907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed working memory training (CWMT)
Number of subjects: 91
Study 25731907 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parent training (BPT)
Number of subjects: 91
Study 25731907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (CWMT and BPT)
Number of subjects: 91
Study 25731907 — intervention group
Group type: COMPARATOR
Intervention: Active control (placebo)
Number of subjects: 91
Study 23413202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparrow sirolimus‐eluting stent (Sparrow‐SES)
Number of subjects: 74
Study 23413202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparrow bare‐metal stent (Sparrow‐BMS)
Number of subjects: 74
Study 23413202 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon‐expandable bare‐metal stent (BMS)
Number of subjects: 74
Study 23518863 — intervention group
Group type: EXPERIMENTAL
Intervention: 52.5 mL of lidocaine 1%
Number of subjects: 90
Study 23518863 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mL of lidocaine 1.5%
Number of subjects: 90
Study 23518863 — intervention group
Group type: EXPERIMENTAL
Intervention: 26.25 mL of lidocaine 2%
Number of subjects: 90
Study 23518863 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1%, 1.5%, 2%)
Number of subjects: 90
Study 23518863 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% group
Number of subjects: 90
Study 23518863 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% group
Number of subjects: 90
Study 21502675 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal band ligation (EVBL)
Number of subjects: 73
Study 21502675 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 73
Study 18316985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DTaP-IPV vaccine
Number of subjects: 4209
Study 18316985 — intervention group
Group type: COMPARATOR
Intervention: Separate DTaP + IPV vaccines
Number of subjects: 4209
Study 17137891 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride as first‐line therapy in addition to conventional therapy
Number of subjects: 26
Study 17137891 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 26
Study 14652415 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin
Number of subjects: 251
Study 14652415 — intervention group
Group type: COMPARATOR
Intervention: Best clinical care alone
Number of subjects: 251
Study 11113426 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockade (atenolol and propranolol)
Number of subjects: 0
Study 11113426 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 9200283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based triple therapy (n = 50)
Number of subjects: 100
Study 9200283 — intervention group
Group type: COMPARATOR
Intervention: Bismuth + placebo (n = 50)
Number of subjects: 100
Study 1305012 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 0
Study 1305012 — intervention group
Group type: COMPARATOR
Intervention: Standard extracapsular cataract extraction (ECCE)
Number of subjects: 0
Study 1305012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical techniques
Number of subjects: 0
Study 3895032 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 4
Study 3895032 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 4
Study 3895032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially Inappropriate Psychotropic drugs (PIP)
Number of subjects: 703
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate background regimen prescription
Number of subjects: 703
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate antidepressant prescription
Number of subjects: 703
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate prescription of anxiolytics
Number of subjects: 703
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate prescription of hypnotics
Number of subjects: 703
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression diagnosis
Number of subjects: 703
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder diagnosis
Number of subjects: 703
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Current major depressive disorder
Number of subjects: 703
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower willingness to ask for help
Number of subjects: 703
Study 30153497 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate background regimen prescription
Number of subjects: 703
Study 29202646 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/1 mL diclofenac HPβCD
Number of subjects: 75
Study 29202646 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg/1 mL diclofenac HPβCD
Number of subjects: 75
Study 29202646 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/1 mL diclofenac HPβCD
Number of subjects: 75
Study 29202646 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/1 mL diclofenac HPβCD
Number of subjects: 75
Study 29202646 — intervention group
Group type: COMPARATOR
Intervention: 1 mL placebo
Number of subjects: 75
Study 27226212 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (human milk)
Number of subjects: 16
Study 27226212 — intervention group
Group type: COMPARATOR
Intervention: 10% sucrose solution
Number of subjects: 16
Study 24636395 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3, 12,000 IU daily for 12 weeks
Number of subjects: 28
Study 24636395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23318611 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb-occlusion-pressure (LOP) group
Number of subjects: 164
Study 23318611 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine method based on patient's systolic blood pressure)
Number of subjects: 164
Study 23318611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with cuff pressure above 225 mm Hg)
Number of subjects: 164
Study 23318611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure ≤225 mm Hg
Number of subjects: 164
Study 20303352 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a with ribavirin
Number of subjects: 50
Study 20303352 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alpha‐2a
Number of subjects: 50
Study 18393052 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine administration
Number of subjects: 0
Study 18393052 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 16581036 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg co-administered with fluoxetine
Number of subjects: 545
Study 16581036 — intervention group
Group type: COMPARATOR
Intervention: Placebo co-administered with fluoxetine
Number of subjects: 545
Study 12672167 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 30
Study 12672167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12672167 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 30
Study 10715508 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aware of being part of a study
Number of subjects: 0
Study 10715508 — intervention group
Group type: COMPARATOR
Intervention: Patients unaware of being part of a study
Number of subjects: 0
Study 9372886 — intervention group
Group type: COMPARATOR
Intervention: External radiotherapy (ER) alone
Number of subjects: 79
Study 9372886 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiotherapy (ER) + strontium-89 (89Sr)
Number of subjects: 79
Study 1549632 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Muscle Test (MMT) grades
Number of subjects: 102
Study 2862882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program for heavy drinkers
Number of subjects: 30000